Xenon Pharmaceuticals Inc
XENE39.094USD
+0.684+1.78%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
3.01BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Xenon Pharmaceuticals Inc Unternehmen
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the Company's lead Kv7 channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. Azetukalner is being developed for the treatment of epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) as well as major depressive disorder (MDD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications. It has an ongoing collaboration with Neurocrine Biosciences, Inc. to develop treatments for epilepsy.
Xenon Pharmaceuticals Inc Informationen
BörsenkürzelXENE
Name des UnternehmensXenon Pharmaceuticals Inc
IPO-datumOct 17, 2014
CEOMr. Ian C. Mortimer, CPA
Anzahl der mitarbeiter316
WertpapierartOrdinary Share
GeschäftsjahresendeOct 17
Addresse3650 Gilmore Way
StadtVANCOUVER
BörseNASDAQ Global Market Consolidated
LandCanada
PostleitzahlV5G 4W8
Telefon16044843300
Websitehttps://www.xenon-pharma.com/
BörsenkürzelXENE
IPO-datumOct 17, 2014
CEOMr. Ian C. Mortimer, CPA
Führungskräfte von Xenon Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Principal Operating Officer, Director
President, Chief Executive Officer, Principal Operating Officer, Director
45.60K
--
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Mr. Thomas J. (Tucker) Kelly, J.D.
Mr. Thomas J. (Tucker) Kelly, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Darren S. Cline
Mr. Darren S. Cline
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
--
--
Dr. Gillian M. Cannon, Ph.D.
Dr. Gillian M. Cannon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Justin Gover
Mr. Justin Gover
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ian C. Mortimer, CPA
Mr. Ian C. Mortimer, CPA
President, Chief Executive Officer, Principal Operating Officer, Director
President, Chief Executive Officer, Principal Operating Officer, Director
45.60K
--
Dr. Gary Patou, M.D.
Dr. Gary Patou, M.D.
Independent Director
Independent Director
28.48K
--
Ms. Dawn A. (Graham) Svoronos
Ms. Dawn A. (Graham) Svoronos
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
25.00K
--
Mr. Steven R. (Steve) Gannon, CPA
Mr. Steven R. (Steve) Gannon, CPA
Independent Director
Independent Director
7.14K
-0.04%
Mr. Thomas J. (Tucker) Kelly, J.D.
Mr. Thomas J. (Tucker) Kelly, J.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Christopher Kenney, M.D.
Dr. Christopher Kenney, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
Canada
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Oct 31
Aktualisiert: Fri, Oct 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
8.29%
Avoro Capital Advisors LLC
6.99%
Driehaus Capital Management, LLC
5.61%
BlackRock Institutional Trust Company, N.A.
5.33%
Braidwell LP
4.67%
Andere
69.12%
Aktionäre
Aktionäre
Anteil
Fidelity Management & Research Company LLC
8.29%
Avoro Capital Advisors LLC
6.99%
Driehaus Capital Management, LLC
5.61%
BlackRock Institutional Trust Company, N.A.
5.33%
Braidwell LP
4.67%
Andere
69.12%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
48.35%
Investment Advisor
33.63%
Hedge Fund
23.40%
Private Equity
1.90%
Research Firm
1.51%
Sovereign Wealth Fund
0.82%
Pension Fund
0.71%
Bank and Trust
0.34%
Individual Investor
0.14%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
446
85.67M
110.86%
-494.45K
2025Q2
418
85.39M
111.27%
+856.94K
2025Q1
434
79.94M
104.19%
-5.23M
2024Q4
434
79.81M
104.31%
-4.80M
2024Q3
425
77.49M
102.39%
-3.82M
2024Q2
431
76.92M
102.03%
-4.12M
2024Q1
421
76.68M
101.81%
-2.76M
2023Q4
404
75.13M
102.42%
+7.65M
2023Q3
386
64.60M
99.41%
-3.93M
2023Q2
377
64.25M
101.09%
-4.03M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fidelity Management & Research Company LLC
6.40M
8.3%
+244.00K
+3.96%
Jun 30, 2025
Avoro Capital Advisors LLC
5.40M
7%
-341.67K
-5.95%
Jun 30, 2025
Driehaus Capital Management, LLC
4.34M
5.62%
-249.21K
-5.44%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.12M
5.34%
+3.47M
+534.85%
Jun 30, 2025
Braidwell LP
3.61M
4.68%
+895.15K
+33.03%
Jun 30, 2025
Janus Henderson Investors
3.58M
4.64%
+252.64K
+7.60%
Jun 30, 2025
Capital International Investors
3.18M
4.13%
+92.82K
+3.01%
Jun 30, 2025
Commodore Capital LP
3.02M
3.92%
+700.00K
+30.11%
Jun 30, 2025
Polar Capital LLP
2.70M
3.51%
+80.22K
+3.06%
Jun 30, 2025
Fidelity Institutional Asset Management
2.48M
3.22%
+352.87K
+16.57%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
iShares Neuroscience and Healthcare ETF
4.25%
ALPS Medical Breakthroughs ETF
1.85%
Goldman Sachs Future Health Care Equity ETF
1.03%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
First Trust Multi-Manager Small Cap Opportunities ETF
0.58%
JPMorgan Fundamental Data Science Small Core ETF
0.52%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.45%
JPMorgan Healthcare Leaders ETF
0.41%
ProShares Ultra Nasdaq Biotechnology
0.32%
Invesco Nasdaq Biotechnology ETF
0.31%
Mehr Anzeigen
iShares Neuroscience and Healthcare ETF
Anteil4.25%
ALPS Medical Breakthroughs ETF
Anteil1.85%
Goldman Sachs Future Health Care Equity ETF
Anteil1.03%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.88%
First Trust Multi-Manager Small Cap Opportunities ETF
Anteil0.58%
JPMorgan Fundamental Data Science Small Core ETF
Anteil0.52%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Anteil0.45%
JPMorgan Healthcare Leaders ETF
Anteil0.41%
ProShares Ultra Nasdaq Biotechnology
Anteil0.32%
Invesco Nasdaq Biotechnology ETF
Anteil0.31%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
